Ondine Biomedical Inc. OBIMF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.61% | -34.61% | -50.21% | -48.14% | -60.02% |
| Total Depreciation and Amortization | -7.41% | -3.15% | 0.00% | -1.36% | 7.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 194.05% | 207.72% | 16.24% | 14.63% | 7.88% |
| Change in Net Operating Assets | -18.95% | -15.17% | 13.02% | 11.48% | 8,620.29% |
| Cash from Operations | -30.85% | -36.95% | -63.31% | -61.06% | -42.06% |
| Capital Expenditure | -368.97% | -390.48% | -- | -- | -135.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -368.97% | -390.48% | -- | -- | -135.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 28.44% | 28.44% | 78.11% | 78.11% | 2.68% |
| Issuance of Common Stock | 58.17% | 58.17% | 19.44% | 19.44% | -4.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,100.00% | -3,100.00% | 1.45% | 1.45% | 96.00% |
| Cash from Financing | 49.42% | 56.40% | 14.05% | 12.48% | 3.51% |
| Foreign Exchange rate Adjustments | -125.45% | -126.67% | -85.02% | -85.24% | 646.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.26% | -25.86% | -41.35% | -42.15% | -143.79% |